inclacumab
mAbexperimental
Inclacumab (LC1004-002) (INN) is a human monoclonal antibody designed for the treatment of cardiovascular disease. — Wikipedia
Clinical trial activity
7 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
5
Phase 3
3
Phase 4
0
Earliest trial started Sep 1, 2008 (NCT00760565)
Timeline
Indications
Mechanism of action
- P-selectinANTAGONIST
SELP antagonist
- P-selectinINHIBITOR
SELP inhibitor
Anti-inflammatory. Blocks monocyte and/or leukocyte penetration into intimal space.
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaInclacumab ↗
- ChEMBLCHEMBL2109650 ↗
- ChEMBLCHEMBL2109488 ↗
Also known as
- inclacumab
- inclacumab
- inclacumab
- lc1004-002
- ro4905417
- ro-4905417
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05348915 | Phase 3 | Mar 29, 2022 | Global Blood Therapeutics, Inc. |
| NCT04927247 | Phase 3 | Oct 29, 2021 | Global Blood Therapeutics, Inc. |
| NCT04935879 | Phase 3 | Oct 26, 2021 | Global Blood Therapeutics, Inc. |
| NCT01815827 | Phase 1 | Jun 1, 2013 | Roche |
| NCT01327183 | Phase 2 | May 1, 2011 | Roche |
| NCT01245634 | Phase 2 | Dec 1, 2010 | Roche |
| NCT00760565 | Phase 1 | Sep 1, 2008 | Roche |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Roche | For profit | 4 | 4 | 2 | 2008 |
| Global Blood Therapeutics, Inc. | For profit | 3 | 3 | 1 | 2021 |
2 organizations
Page 1 / 1